Clinical effect of iodine 125 seeds implantation synchronized chemotherapy with docetaxel, cisplatin, 5-fluorouracil for unresectable head and neck squamous cell carcinoma

doi:10.3877/cma.j.issn.1674-1366.2015.05.008

Abstract

Abstract:

Objective

To discuss the feasibility and safety of radioactive Iodine 125 seeds implantation synchronized chemotherapy with docetaxel, cisplatin, 5-fluorouracil (TPF) on advanced unresectable head and neck squamous cell carcinoma (HNSCC) .

Methods

Previously untreated patients with histologically documented advanced unresectable HNSCC underwent percutaneous radioative iodine 125 seeds interstitial implantation, and simultaneously received three cycles of chemotherapy every 21 days at a dose of 75 mg/m² docetaxel D1, 75 mg/m² cisplatin D1, 750 mg/m² 5-fluorouracil D2~5.

Results

The effectiveness of treament was evaluated based on tumor size and clinical symptoms in patients. The overall responding was 78.3%. A progression-free survival of 60.9% and overall survival of 52.2% was achieved at 2 years. Four each died of cardiovascular and local recurrence. Major toxicities included leucopenia, alopecia, nausea/vomiting, local hemorrhage, thrombocytopenia. No acute complications and treatment related raidation damages occurred in the trail.

Conclusion

The scheme of brachytherapy based on iodine 125 seeds implantation synchronized chemotherapy is a mild invasive, effective and safety regimen of advanced head and neck squamous cell carcinoma.

Key words: Head and neck squamous cell carcinoma, Brachytherapy, Concurrent chemoradiotherapy, Iodine 125 seeds implantation, Treatment plan system

Xing Wang, Jian Meng, Qianping Gu, Jie Zhang, Jianmin Gu, Kun Han. Clinical effect of iodine 125 seeds implantation synchronized chemotherapy with docetaxel, cisplatin, 5-fluorouracil for unresectable head and neck squamous cell carcinoma[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2015, 09(05): 395-399.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhkqyxyjzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1366.2015.05.008

https://zhkqyxyjzz.cma-cmc.com.cn/EN/Y2015/V09/I05/395

Figures/Tables 4

References 20

[1]	Al-Swiahb JN，Chen CH，Chuang HC，et al. Clinical，pathological and molecular determinants in squamous cell carcinoma of the oral cavity[J]. Future Oncol，2010，6(5):837-850.
[2]	Agarwal JP，Nemade B，Murthy V，et al. Hypofractionated，palliative radiotherapy for advanced head and neck cancer[J]. Radiother Oncol，2008，89(1):51-56.
[3]	Das S，Thomas S，Pal SK，et al. Hypofractionated palliative radiotherapy in locally advanced inoperable head and neck cancer：CMC Vellore experience[J]. Indian J Palliat Care，2013，19(2):93-98.
[4]	Mohanti BK，Umapathy H，Bahadur S，et al. Short course palliative radiotherapy of 20 Gy in 5 fractions for advanced and incurable head and neck cancer：AIIMS study[J]. Radiother Oncol，2004，71(3):275-280.
[5]	Calais G，Alfonsi M，Bardet E，et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma[J]. J Natl Cancer Inst，1999，91(24):2081-2086.
[6]	Meng J，Meng QF，Gu QP，et al. Radioactive seed implantation combined with prosthesis denture in treatment of oral and maxillofacial malignancy[J]. Cell Biochem Biophys，2013，67(3):1529-1532.
[7]	王兴，孟箭. ¹²⁵I植入联合尼妥珠单抗治疗头颈部恶性肿瘤的近期疗效及安全性评价[J/CD]. 中华临床医师杂志：电子版，2013，7(13):6152-6154.
[8]	Gomez-Roca C，Koscielny S，Ribrag V，et al. Tumour growth rates and RECIST criteria in early drug development[J]. Eur J Cancer，2011，47(17):2512-2516.
[9]	Denis F，Garaud P，Bardet E，et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma：comparison of LENT/SOMA，RTOG/EORTC，and NCI-CTC scoring systems[J]. Int J Radiat Oncol Biol Phys，2003，55(1):93-98.
[10]	Ahn JS，Cho SH，Kim OK，et al. The efficacy of an induction chemotherapy combination with docetaxel，cisplatin，and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer[J]. Cancer Res Treat，2007，39(3):93-98.
[11]	Semrau S，Schmidt D，Lell M，et al. Results of chemoselection with short induction chemotherapy followed by chemoradiationor surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx[J]. Oral Oncol，2013，49(5):454-460.
[12]	Lyman GH，Dale DC，Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy：a nationwide study of community practices[J]. J Clin Oncol，2003，21(24):4524-4531.
[13]	Jiang YL，Meng N，Wang JJ，et al. Percutaneous computed tomography/ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent squamous cell cancers of head and neck[J]. Cancer Biol Ther，2010，9(12):959-966.
[14]	Ruge MI，Simon T，Suchorska B，et al. Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children：long-term outcome[J]. J Clin Oncol，2011，29(31):4151-4159.
[15]	Ruge MI，Kickingereder P，Grau S，et al. Stereotactic iodine-125 brachytherapy for the treatment of WHO grades Ⅱ and Ⅲ gliomaslocated in the central sulcus region[J]. Neuro Oncol，2013，15(12):1721-1731.
[16]	王兴，孟箭. ¹²⁵I粒子植入治疗高龄非霍奇金淋巴瘤并吞咽困难一例[J]. 中华全科医师杂志，2015，14(5):388-389.
[17]	Khalilur R，Hayashi K，Shibuya H. Brachytherapy for tongue cancer in the very elderly is an alternative to external beamradiation[J]. Br J Radiol，2011，84(1004):747-749.
[18]	Zhang L，Chen LH，Wang J，et al. CT-guided radioactive ¹²⁵I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma[J]. Clin Radiol，2014，69(6):624-629.
[19]	Jiang YL，Meng N，Wang JJ，et al. CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers[J]. Radiat Oncol，2010(5):68.
[20]	Zheng L，Zhang J，Zhang J，et al. Preliminary results of ¹²⁵I interstitial brachytherapy for locally recurrent parotidgland cancer in previously irradiated patients[J]. Head Neck，2012，34(10):1445-1449.

项目		患者数	项目		患者数
性别		?	原发灶情况		?
?	男	15（65.2）	?	T₁	0（0）
?	女	8（34.8）	?	T₂	4（17.4）
ECOG生活质量评分		?	?	T₃	10（43.5）
?	0分	3（13.0）	?	T₄	9（39.1）
?	1分	6（26.1）	淋巴结转移		?
?	2分	12（52.2）	?	N₀	5（21.7）
?	3分	2（8.7）	?	N₁	3（13.1）
临床分期		?	?	N₂	14（60.9）
?	Ⅲ期	5（21.7）	?	N3	1（4.3）
?	Ⅳa期	15（65.2）	?	?	?
?	Ⅳb期	3（13.1）	?	?	?

项目		患者数	项目		患者数
性别		?	原发灶情况		?
?	男	15（65.2）	?	T₁	0（0）
?	女	8（34.8）	?	T₂	4（17.4）
ECOG生活质量评分		?	?	T₃	10（43.5）
?	0分	3（13.0）	?	T₄	9（39.1）
?	1分	6（26.1）	淋巴结转移		?
?	2分	12（52.2）	?	N₀	5（21.7）
?	3分	2（8.7）	?	N₁	3（13.1）
临床分期		?	?	N₂	14（60.9）
?	Ⅲ期	5（21.7）	?	N3	1（4.3）
?	Ⅳa期	15（65.2）	?	?	?
?	Ⅳb期	3（13.1）	?	?	?

部位	例数	CR	PR	SD	PD	有效率（%）
舌	9	2	5	1	1	77.8
颊黏膜	5	3	1	1	0	80.0
口底	7	1	4	1	1	71.4
腮腺	2	2	0	0	0	100.0

部位	例数	CR	PR	SD	PD	有效率（%）
舌	9	2	5	1	1	77.8
颊黏膜	5	3	1	1	0	80.0
口底	7	1	4	1	1	71.4
腮腺	2	2	0	0	0	100.0

Please choose a citation manager

Content to export